Abstract：【Objective】To study the value of serum SCCA and miR-501 in the clinical diagnosis and prognosis of patients with cervical cancer. 【Methods】Sixty patients with cervical cancer admitted to the Oncology Department in our hospital from January 2018 to June 2020 were selected as the research objects and served as the observation group. A total of 60 healthy physical examination volunteers in the same period were selected as the control group. The serum SCCA and miR-501 levels of the two groups were compared. At the same time, the observation group's disease stage, lymph node metastasis, pathological differentiation and histopathological classification were counted, and the relationship of serum SCCA and miR-501 levels with the patient's disease characteristics was analyzed. 【Results】The serum SCCA and miR-501 levels of the observation group were significantly higher than those of the control group(P<0.05). Serum SCCA and miR-501 were the best for diagnosis of cervical cancer The cut-off points are 15.2 ng/ml and 0.73, respectively. Serum SCCA and miR-501 levels increased with the increase of cervical cancer stage. The difference between stage Ⅰ, stage Ⅱ and stage Ⅲ was statistically significant(P<0.05), and the difference between stage Ⅲ and stage Ⅳ was not statistically significant(P>0.05). Serum SCCA and miR-501 levels increased with the decrease of cervical cancer pathological differentiation, and those with lymph node metastasis were significantly higher than those without lymph node metastasis, with statistically significant difference(P<0.05). The serum SCCA of patients with squamous cell carcinoma was significantly higher than that of patients with adenocarcinoma, and the difference was statistically significant(P<0.05). The level of serum miR-501 in patients with squamous cell carcinoma was significantly higher than that of adenocarcinoma. The difference between patients was not statistically significant(P>0.05). The area under the ROC curve for the diagnosis of cervical cancer by serum SCCA and miR-501 levels were 0.869(95% CI:0.809~0.929) and 0.911(95% CI:0.861~0.961), respectively. The best cut-off points of serum SCCA and miR-501 for diagnosis of cervical cancer were 15.2 ng/mL and 0.73, respectively. The OS of SCCA≤15.2 ng/ml was significantly longer than that of SCCA>15.2 ng/ml(P<0.05), and the OS of miR-501≤0.73 was significantly longer than that of miR-501>0.73(P<0.05). 【Conclusion】Serum SCCA and miR-501 levels can be used to assist clinical diagnosis of cervical cancer, predict the malignant degree of cervical cancer, histopathological classification and patient prognosis.
张涛, 刘宁宁, 田睿红. SCCA、miR-501在宫颈癌患者血清中的表达水平及临床意义[J]. 医学临床研究, 2021, 38(7): 1024-1027.
ZHANG Tao, LIU Ning-ning, TIAN Rui-hong. Analysis of Serum SCCA and MiR-501 in Clinical Diagnosis and Prognostic Value of Cervical Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(7): 1024-1027.
[1] BERMUDEZ A.Cancer of the cervix uteri[J].Int J Gynaecol Obstet,2015,131 (Suppl 2):S88-S95. [2] KESSLER T A. Cervical Cancer:Prevention and Early Detection[J].Semin Oncol Nurs,2017,33(2):172-183. [3] LAHUE B J, BAGINSKA E, LI S S, et al. Health technology assessment on cervical cancer screening, 2000-2014[J].Int J Technol Assess Health Care,2015,31(3):171-180. [4] POZZAN C, CARDIN R, PICIOCCHI M, et al. Diagnostic and prognostic role of SCCA-IgM serum levels in hepatocellular carcinoma(HCC) [J].J Gastroenterol Hepatol,2014,29(8):1637-1644. [5] YOON S M, SHIN K H, KIM J Y, et al. Use of serum squamous cell carcinoma antigen for follow-up monitoring of cervical cancer patients who were treated by concurrent chemoradiotherapy[J].Radiat Oncol,2010,5:78. [6] SANCHES J G P, XU Y, YABASIN I B, et al. miR-501 is upregulated in cervical cancer and promotes cell proliferation, migration and invasion by targeting CYLD[J].Chem Biol Interact,2018,285:85-95. [7] KOH W J, GREER B E, ABU-RUSTUM N R, et al. Cervical Cancer, Version 2.2015[J].J Natl Compr Canc Netw,2015,13(4):395-404. [8] ZHOU Z, LI W, ZHANG F, et al. The value of squamous cell carcinoma antigen(SCCa) to determine the lymph nodal metastasis in cervical cancer:a meta-analysis and literature review[J].PLoS One,2017,12(12):e0186165. [9] MADDALO G, FASSAN M, CARDIN R, et al. Squamous cellular carcinoma antigen serum determination as a biomarker of barrett esophagus and esophageal cancer:a phase iii study[J].J Clin Gastroenterol,2018,52(5):401-406. [10] HAN C, ZHAO F, WAN C, et al. Associations between the expression of SCCA, MTA1, P16, Ki-67 and the infection of high-risk HPV in cervical lesions[J].Oncol Lett,2020,20(1):884-892. [11] BANNO K, IIDA M, YANOKURA M, et al. MicroRNA in cervical cancer:OncomiRs and tumor suppressor miRs in diagnosis and treatment[J].Sci World J,2014,2014:178075.
2021, Vol. 38 
